1. Home
  2. CRSP vs FNB Comparison

CRSP vs FNB Comparison

Compare CRSP & FNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • FNB
  • Stock Information
  • Founded
  • CRSP 2013
  • FNB 1864
  • Country
  • CRSP Switzerland
  • FNB United States
  • Employees
  • CRSP N/A
  • FNB N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • FNB Major Banks
  • Sector
  • CRSP Health Care
  • FNB Finance
  • Exchange
  • CRSP Nasdaq
  • FNB Nasdaq
  • Market Cap
  • CRSP 4.3B
  • FNB 5.1B
  • IPO Year
  • CRSP 2016
  • FNB N/A
  • Fundamental
  • Price
  • CRSP $43.65
  • FNB $15.51
  • Analyst Decision
  • CRSP Buy
  • FNB Buy
  • Analyst Count
  • CRSP 18
  • FNB 6
  • Target Price
  • CRSP $76.60
  • FNB $17.67
  • AVG Volume (30 Days)
  • CRSP 1.8M
  • FNB 2.0M
  • Earning Date
  • CRSP 11-05-2024
  • FNB 01-16-2025
  • Dividend Yield
  • CRSP N/A
  • FNB 3.10%
  • EPS Growth
  • CRSP N/A
  • FNB N/A
  • EPS
  • CRSP N/A
  • FNB 1.09
  • Revenue
  • CRSP $202,829,000.00
  • FNB $1,492,800,000.00
  • Revenue This Year
  • CRSP N/A
  • FNB N/A
  • Revenue Next Year
  • CRSP $758.18
  • FNB $4.66
  • P/E Ratio
  • CRSP N/A
  • FNB $14.19
  • Revenue Growth
  • CRSP 19.31
  • FNB N/A
  • 52 Week Low
  • CRSP $42.86
  • FNB $12.49
  • 52 Week High
  • CRSP $91.10
  • FNB $17.70
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 39.11
  • FNB 38.60
  • Support Level
  • CRSP $43.40
  • FNB $15.33
  • Resistance Level
  • CRSP $53.97
  • FNB $16.67
  • Average True Range (ATR)
  • CRSP 2.37
  • FNB 0.33
  • MACD
  • CRSP -0.78
  • FNB -0.21
  • Stochastic Oscillator
  • CRSP 9.53
  • FNB 10.40

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About FNB F.N.B. Corporation

F N B Corp provides a full range of financial services, principally to consumers, corporations, governments and small- to medium-sized businesses. It has three reportable business segments: Community Banking, Wealth Management and Insurance. The majority of revenue is from the Community banking segment. It offers commercial & consumer banking services. Commercial banking solutions include corporate banking, small business banking, investment real estate financing, business credit, capital markets & lease financing. Consumer banking products & services include deposit products, mortgage lending, & consumer lending & a complete suite of mobile & online banking services.

Share on Social Networks: